Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.32, beating the estimate of USD -0.356.

EBIT: As of FY2026 Q1, the actual value is USD -21.77 M.

Financial Performance for the Three Months Ended March 31, 2026

• Research and Development (R&D) Expenses: Pliant Therapeutics, Inc. reported R&D expenses of - $13.6 million for the first quarter of 2026, a decrease compared to - $43.4 million in the prior-year quarter, primarily due to the completion of close-out activities for the BEACON-IPF study in 2025 and reduced personnel-related expenses from decreased headcount.
• General and Administrative (G&A) Expenses: G&A expenses were - $8.2 million for the first quarter of 2026, down from - $15.5 million in the prior-year quarter, mainly due to lower personnel-related expenses, including stock-based compensation, resulting from a reduced headcount.
• Net Loss: The company’s net loss for the first quarter of 2026 was - $20.0 million, an improvement from a net loss of - $56.2 million in the prior-year quarter, driven by significantly lower operating expenses following the termination of bexotegrast development in IPF in 2025 and decreased personnel-related expenses.
• Interest and Other Income (Expense), Net: Interest and other income (expense), net was $1.7 million in the first quarter of 2026, compared to $3.6 million in the prior-year quarter.
• Interest Expense: There was no interest expense reported for the first quarter of 2026, compared to - $0.8 million in the prior-year quarter.

Financial Position as of March 31, 2026

• Cash, Cash Equivalents, and Short-Term Investments: As of March 31, 2026, Pliant Therapeutics, Inc. held $172.4 million in cash, cash equivalents, and short-term investments, comprising $22.2 million in cash and cash equivalents and $148.7 million in short-term investments.
• Total Current Assets: Total current assets were $174.9 million as of March 31, 2026, compared to $196.4 million as of December 31, 2025.
• Total Assets: Total assets were $202.6 million as of March 31, 2026, down from $225.2 million as of December 31, 2025.
• Total Current Liabilities: Total current liabilities were $10.4 million as of March 31, 2026, compared to $16.4 million as of December 31, 2025.
• Total Liabilities: Total liabilities were $37.4 million as of March 31, 2026, compared to $44.0 million as of December 31, 2025.
• Total Stockholders’ Equity: Total stockholders’ equity was $165.2 million as of March 31, 2026, compared to $181.2 million as of December 31, 2025.

Operational Highlights and Outlook

• Operational Metrics: Pliant Therapeutics, Inc. initiated FORTIFY, a Phase 1b indication expansion trial for PLN-101095, ahead of schedule, with the first participant dosed in April 2026. The company continues to advance its proprietary integrin-targeted delivery platform with ongoing preclinical proof-of-concept studies.
• Financial Outlook: Pliant Therapeutics, Inc. expects its $172.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026, to be sufficient to fund operations into the second half of 2028.